{"id":941963,"date":"2026-03-04T09:33:01","date_gmt":"2026-03-04T14:33:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/"},"modified":"2026-03-04T09:33:01","modified_gmt":"2026-03-04T14:33:01","slug":"autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/","title":{"rendered":"Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis"},"content":{"rendered":"
\n

\n THE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) — <\/b>
\n Autonomix Medical, Inc.<\/a>\u00a0(NASDAQ: AMIX) (\u201cAutonomix\u201d or the \u201cCompany\u201d), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Nikola Cesarovic, PhD, will present clinical feasibility and outcome data at the Cardiovascular Research Technologies (CRT) 2026 Meeting<\/a>, happening March 7-10, 2026, in Washington, DC.<\/p>\n

The abstract titled, \u201cNovel Technique For Transvascular Peripheral Nerve Neurolysis Using Radiofrequency (RF) Ablation: Clinical Feasibility And Outcomes<\/i>,\u201d will be presented during the Top Abstract Session (S194) on Saturday, March 7 from 2:18 – 2:24p ET for Hypertension Therapies and Renal Denervation session. Dr. Cesarovic will deliver a six-minute presentation, highlighting clinical feasibility and early outcomes associated with a novel RF-based approach designed to selectively disrupt peripheral nerve activity via a transvascular approach. Autonomix\u2019s technology is engineered to identify and target specific nerve signals, potentially enabling differentiated therapeutic precision compared to conventional ablation techniques.<\/p>\n

\u201cThis Top Abstract selection underscores the growing clinical interest in precision nerve-targeted therapies and highlights the potential of Autonomix\u2019s platform to enable controlled, transvascular peripheral nerve modulation,\u201d said Dr. Robert Schwartz, Co-Founder and Chief Medical Officer of Autonomix. \u201cWe believe these early feasibility findings support the broader applicability of our technology across multiple indications where peripheral nerve signaling plays a critical role.\u201d<\/p>\n

CRT is one of the world\u2019s leading educational forums for interventional cardiovascular medicine, with Top Abstract podium selections representing the highest-scoring submissions based on scientific merit, innovation and clinical relevance. For more information, please visit the conference website here<\/a>.<\/p>\n

\n About Autonomix Medical, Inc.<\/b>\n <\/p>\n

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company\u2019s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.<\/p>\n

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.<\/p>\n

For more information, visit\u00a0autonomix.com<\/a> and connect with the Company on X<\/a>, LinkedIn<\/a>, Instagram<\/a> and Facebook<\/a>.<\/p>\n

\n Forward Looking Statements<\/b>\n <\/p>\n

Some of the statements in this release are \u201cforward-looking statements,\u201d which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as \u201cshould,\u201d \u201cmight,\u201d \u201cmay,\u201d \u201cintends,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cprojects,\u201d \u201cforecasts,\u201d \u201cexpects,\u201d \u201cplans,\u201d and \u201cproposes.\u201d Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix’s nerve-targeted treatments for pancreatic cancer pain and other conditions.<\/p>\n

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading \u201cRisk Factors\u201d and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.<\/p>\n

\n Investor and Media Contact<\/b>\n <\/p>\n

JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

THE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc.\u00a0(NASDAQ: AMIX) (\u201cAutonomix\u201d or the \u201cCompany\u201d), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Nikola Cesarovic, PhD, will present clinical feasibility and outcome data at the Cardiovascular Research Technologies (CRT) 2026 Meeting, happening March 7-10, 2026, in Washington, DC. The abstract titled, \u201cNovel Technique For Transvascular Peripheral Nerve Neurolysis Using Radiofrequency (RF) Ablation: Clinical Feasibility And Outcomes,\u201d will be presented during the Top Abstract Session (S194) on Saturday, March 7 from 2:18 – 2:24p ET for Hypertension Therapies and Renal Denervation session. Dr. Cesarovic will deliver a six-minute presentation, highlighting clinical feasibility and early outcomes associated with a novel RF-based approach designed to selectively … <\/p>\n

Continue reading “Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-941963","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAutonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"THE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc.\u00a0(NASDAQ: AMIX) (\u201cAutonomix\u201d or the \u201cCompany\u201d), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Nikola Cesarovic, PhD, will present clinical feasibility and outcome data at the Cardiovascular Research Technologies (CRT) 2026 Meeting, happening March 7-10, 2026, in Washington, DC. The abstract titled, \u201cNovel Technique For Transvascular Peripheral Nerve Neurolysis Using Radiofrequency (RF) Ablation: Clinical Feasibility And Outcomes,\u201d will be presented during the Top Abstract Session (S194) on Saturday, March 7 from 2:18 – 2:24p ET for Hypertension Therapies and Renal Denervation session. Dr. Cesarovic will deliver a six-minute presentation, highlighting clinical feasibility and early outcomes associated with a novel RF-based approach designed to selectively … Continue reading "Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-04T14:33:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTQxOSM3NDY2NDA0IzUwMDExOTk5Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis\",\"datePublished\":\"2026-03-04T14:33:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\\\/\"},\"wordCount\":649,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NTQxOSM3NDY2NDA0IzUwMDExOTk5Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\\\/\",\"name\":\"Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NTQxOSM3NDY2NDA0IzUwMDExOTk5Mg==\",\"datePublished\":\"2026-03-04T14:33:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NTQxOSM3NDY2NDA0IzUwMDExOTk5Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NTQxOSM3NDY2NDA0IzUwMDExOTk5Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/","og_locale":"en_US","og_type":"article","og_title":"Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis - Market Newsdesk","og_description":"THE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc.\u00a0(NASDAQ: AMIX) (\u201cAutonomix\u201d or the \u201cCompany\u201d), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Nikola Cesarovic, PhD, will present clinical feasibility and outcome data at the Cardiovascular Research Technologies (CRT) 2026 Meeting, happening March 7-10, 2026, in Washington, DC. The abstract titled, \u201cNovel Technique For Transvascular Peripheral Nerve Neurolysis Using Radiofrequency (RF) Ablation: Clinical Feasibility And Outcomes,\u201d will be presented during the Top Abstract Session (S194) on Saturday, March 7 from 2:18 – 2:24p ET for Hypertension Therapies and Renal Denervation session. Dr. Cesarovic will deliver a six-minute presentation, highlighting clinical feasibility and early outcomes associated with a novel RF-based approach designed to selectively … Continue reading \"Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-04T14:33:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTQxOSM3NDY2NDA0IzUwMDExOTk5Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis","datePublished":"2026-03-04T14:33:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/"},"wordCount":649,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTQxOSM3NDY2NDA0IzUwMDExOTk5Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/","name":"Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTQxOSM3NDY2NDA0IzUwMDExOTk5Mg==","datePublished":"2026-03-04T14:33:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTQxOSM3NDY2NDA0IzUwMDExOTk5Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NTQxOSM3NDY2NDA0IzUwMDExOTk5Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autonomix-medical-selected-as-top-abstract-at-crt-2026-and-selected-for-podium-presentation-of-clinical-feasibility-and-outcomes-of-novel-technique-for-transvascular-peripheral-rf-nerve-neurolysis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=941963"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/941963\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=941963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=941963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=941963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}